Trial approved in UK for GenSight gene therapy for retinitis pigmentosa

The Medicines and Healthcare Products Regulatory Agency in the United Kingdom has accepted a clinical trial application from GenSight Biologics for the PIONEER phase 1/2 study of its gene therapy GS030 for patients with retinitis pigmentosa, according to a company press release.
The first-in-man, multicenter, open-label, dose-escalation study will evaluate the safety and tolerability of the therapy, which utilizes GenSight’s optogenetics technology platform to introduce gene encoding for a light-sensitive protein into specifically targeted retinal cells, the release said.
“I am

Full Story →